clinical cancer advances 2011
DESCRIPTION
Clinical Cancer Advances 2011. ASCO’s seventh annual Clinical Cancer Advances report identifies this year’s most significant clinical cancer advances Highlights 12 most important advances, along with 42 other notable advances in prevention and screening, treatment, and survivorship - PowerPoint PPT PresentationTRANSCRIPT
www.cancer.net/cca
Clinical Cancer Advances 2011• ASCO’s seventh annual Clinical Cancer Advances
report identifies this year’s most significant clinical cancer advances
• Highlights 12 most important advances, along with 42 other notable advances in prevention and screening, treatment, and survivorship
• Overseen by 18-member editorial board of oncologists
• Complete 2011 CCA report is available:– Interactive PDF at www.cancer.net/cca– Published in the Journal of Clinical Oncology, www.jco.org
www.cancer.net/cca
Top Advances of 2011 New therapy for advanced melanoma CT screening reduced lung cancer deaths FDA approved new therapies for 2 hard-to-
treat cancers: lung cancer and melanoma High-dose chemotherapy regimen improves
survival in children with neuroblastoma Aromatase inhibitor reduced the risk of a
first breast cancer
www.cancer.net/cca
Top 12 Advances1. BRAF Inhibitor Improves Survival in Advanced Melanoma
Phase III trial showed vemurafenib (Zelboraf®) improved overall survival in patients with advanced melanoma when compared to standard therapy
The therapy targets a common mutation in melanoma in the BRAF gene
About ½ of patients have tumors that carry this mutation Vemurafenib was FDA approved in August 2011
www.cancer.net/cca
Top 12 Advances2. Low-Dose CT Scan Reduces Lung Cancer
Death Rate in People at High Risk National screening trial of more than 50,000
current- and former-heavy smokers Found three annual low-dose CT scans reduced risk
of dying from lung cancer by 20% Results were compared patients screened with
three annual chest X-rays
www.cancer.net/cca
Top 12 Advances3. FDA Approves Crizotinib (Xalkori®) for
Lung Cancer FDA approved crizotinib in August 2011 for
patients with advanced non-small cell lung cancer whose tumors harbor a specific type of alteration in the anaplastic lymphoma kinase (ALK) gene
In studies, the treatment was found to improve survival by 31 percent after two years
www.cancer.net/cca
Top 12 Advances4. First-Line Ipilimumab Plus
Chemotherapy Improves Survival in Metastatic Melanoma Phase III study found ipilimumab (Yervoy®) plus
dacarbazine improved overall survival by 2 months in patients with previously untreated metastatic melanoma, compared to chemo alone
Ipilimumab is an immune therapy that activates the immune system’s T cells
Ipilimumab was FDA approved in March 2011
www.cancer.net/cca
Top 12 Advances5. New Chemo Regimen Boosts Survival for
Children and Young Adults with ALL Phase III Children’s Oncology Group trial of nearly
2,500 children and young adults with acute lymphoblastic leukemia (ALL)
Showed methotrexate given in large, consistent doses, rather than gradually increasing doses of the standard regimen, was more effective in preventing relapse and improving survival
Findings set new standard of care and pushed cure rates for pediatric ALL patients to more than 80%
www.cancer.net/cca
Top 12 Advances6. Exemestane Reduces Risk of Invasive
Breast Cancer Phase III trial of the aromatase inhibitor (AI)
exemestane compared with placebo Found the AI reduced risk of developing breast
cancer in high-risk, postmenopausal women First conclusive evidence that an AI reduced risk
of a first breast cancer
www.cancer.net/cca
Top 12 Advances7. Bevacizumab Delays Progression in
Recurrent Ovarian Cancers Two randomized Phase III trials found women with
recurrent ovarian cancer who received combination therapy lived significantly longer without their disease worsening than those who received chemo alone1. First trial (OCEANS) found patients treated with
bevacizumab lived a median of four months longer without disease progression than those with chemo alone
www.cancer.net/cca
Top 12 Advances8. Bevacizumab Delays Progression in Recurrent
Ovarian Cancers Two randomized Phase III trials found women with
recurrent ovarian cancer who received combination therapy lived significantly longer without their disease worsening than those who received chemo alone1. First trial (OCEANS) found patients treated with bevacizumab lived
a median of four months longer without disease progression than those with chemo alone
2. Second trial data suggested bevacizumab added to standard carboplatin and paclitaxel chemo for newly diagnosed ovarian cancer patients, particularly those with more aggressive disease, helps women live longer than with chemo alone
www.cancer.net/cca
Top 12 Advances9. Imatinib Therapy Improves Survival for
High-Risk GIST Phase III trial showed 3 years of treatment with imatinib
(Gleevec®) after surgery in patients with high-risk gastrointestinal stromal tumors (GIST) significantly improved overall and recurrence-free survival compared to one year of treatment
Findings could result to three-year course of therapy becoming new standard of care for patients at risk for relapse
www.cancer.net/cca
Top 12 Advances10. New Chemo Regimen Improves Survival
in Children with Neuroblastoma Phase III trial showed a new high-dose combination of
chemotherapy drugs improved survival for children with high-risk metastatic neuroblastoma
At 3 years, event-free survival rate for patients treated with intense dosing of busulphan-melphalan was 49% compared to 33% for the standard chemotherapy drugs carboplatin, etoposide and melphalan
These findings establish a new standard of care for high-risk neuroblastoma
www.cancer.net/cca
Top 12 Advances11. RNI Decreases Recurrence in Women
with Early Breast Cancer Analysis of a randomized phase III trial found adding
radiation to the regional lymph nodes reduces risk of cancer recurrence both near the tumor and in other parts of the body
Findings apply to women with early-stage breast cancer who have one to three cancer-positive lymph nodes (or high-risk node-negative breast cancer)
www.cancer.net/cca
Top 12 Advances12. Abiraterone Acetate FDA Approved for
Prostate Cancer The FDA approved the oral agent abiraterone
acetate (Zytiga®) in combination with prednisone for patients with metastatic hormone-refractory prostate cancer who have received prior treatment with docetaxel
The drug works by blocking production of male sex hormones that fuel the growth of prostate tumors
www.cancer.net/cca
2011 Cancer Policy Developments Progress against cancer Transforming clinical cancer research Progress made in revitalizing
federally funded clinical trials Potential impact of healthcare reform
on cancer disparities Severe cancer drug shortages gain
attention of media and congress
ASCO Blueprint: www.asco.org/blueprint
www.cancer.net/cca
2011 Cancer Policy Developments Severe cancer drug shortages gain
attention of media and congress ASCO takes steps to improve
advanced cancer care planning Research highlights potential
solutions for oncology workforce shortages
United Nations Summit addresses cancer crisis in developing countries
www.cancer.net/cca
ASCO ResourcesASCO Guidelineswww.asco.org/guidelines
Conquer Cancer Foundationwww.ccf.org
Cancer.netwww.cancer.net
ASCO Connectionhttp://connection.asco.org
www.cancer.net/cca
ASCO ResourcesCancer Progresswww.cancerprogress.net
The cancerprogress.net site provides a dynamic and interactive history of progress against cancer, expert perspective on remaining challenges and other useful tools
ASCO’s Annual Report on
Progress Against Cancer
www.cancer.net/cca
For additional information, contact
Susie Tappouni in ASCO’s Communications Department: